3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lung Neoplasms
1
Interventions
pembrolizumab
524
Specimen Handling
383
Carboplatin
377
Magnetic Resonance Spectroscopy
336
Cisplatin
332
Nivolumab
308
Cyclophosphamide
298
Radiotherapy
257
Paclitaxel
255
Gemcitabine
235
Biopsy
235
Bevacizumab
218
Dexamethasone
169
durvalumab
168
Oxaliplatin
163
Capecitabine
158
Rituximab
157
Fluorouracil
149
venetoclax
147
Docetaxel
147
Etoposide
142
Drug Therapy
142
atezolizumab
141
Doxorubicin
134
Ipilimumab
129
Radiosurgery
120
Prednisone
120
Lenalidomide
119
Leucovorin
113
fludarabine
109
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Histamine H2 Antagonists
×
1 year
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled